Intralesional treatment with meglumine antimoniate in three patients with New World cutaneous leishmaniasis and large periarticular lesions with comorbidities

• Autor(a) principal: Pimentel,Maria Inês Fernandes
• Data de Publicação: 2017
• Outros Autores: Vasconcellos,Érica de Camargo Ferreira e, Ribeiro,Carla de Oliveira, Lyra,Marcelo Rosandiski, Saheki,Mauricio Naoto, Salgueiro,Mariza de Matos, Antonio,Liliane de Fátima, Schubach,Armando de Oliveira
• Tipo de documento: Relatório
• Idioma: eng
• Título da fonte: Revista da Sociedade Brasileira de Medicina Tropical
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0037-86822017000200269
• topic: Cutaneous leishmaniasis; Meglumine antimoniate; Intralesional injections

Abstract Although New World cutaneous leishmaniasis is not itself a life-threatening disease, its treatment with systemic antimonials can cause toxicity that can be dangerous to some patients. Intralesional meglumine antimoniate provides a viable, less toxic alternative. Herein, we describe an alternative treatment with subcutaneous intralesional injections of meglumine antimoniate into large periarticular lesions of three patients with cutaneous leishmaniasis and comorbidities. This treatment was safe, successful, and well tolerated. This case series suggests that intralesional meglumine antimoniate is an effective therapy for cutaneous leishmaniasis, even with periarticular lesions. This hypothesis should be tested in controlled clinical trials.